Loading...
XNASXYLO
Market cap6mUSD
Dec 24, Last price  
3.64USD
1D
3.70%
1Q
4.00%
IPO
-47.90%
Name

Medigus Ltd

Chart & Performance

D1W1MN
XNAS:XYLO chart
P/E
—
P/S
0.08
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
64.50%
Rev. gr., 5y
191.47%
Revenues
92m
-0.15%
0000549,000467,000436,000273,000531,00010,118,00091,858,00091,724,000
Net income
-16m
L+56.98%
0000-9,007,000-2,545,000-6,598,000-14,178,000-6,850,0004,046,000-10,208,000-16,025,000
CFO
-6m
L+10.45%
0000-9,265,000-4,681,000-4,222,000-2,695,000-6,143,000-5,250,000-5,656,000-6,247,000

Profile

Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, visualization solutions, and resistant cameras; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.
URL
https://medigus.com/
IPO date
Feb 27, 2006
Employees
77
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
91,724
-0.15%
91,858
807.87%
10,118
1,805.46%
Cost of revenue
102,539
100,439
18,314
Unusual Expense (Income)
NOPBT
(10,815)
(8,581)
(8,196)
NOPBT Margin
Operating Taxes
(74)
111
105
Tax Rate
NOPAT
(10,741)
(8,692)
(8,301)
Net income
(16,025)
56.98%
(10,208)
-352.30%
4,046
-159.07%
Dividends
(1,583)
Dividend yield
Proceeds from repurchase of equity
466
12,567
18,724
BB yield
Debt
Debt current
9,084
6,742
927
Long-term debt
1,272
4,036
689
Deferred revenue
Other long-term liabilities
26
125
733
Net debt
(5,947)
(27,407)
(44,566)
Cash flow
Cash from operating activities
(6,247)
(5,656)
(5,250)
CAPEX
(1,747)
(74)
(141)
Cash from investing activities
(1,438)
(4,476)
(12,446)
Cash from financing activities
(3,149)
5,410
19,150
FCF
(10,591)
(9,614)
(7,929)
Balance
Cash
12,536
25,050
27,340
Long term investments
3,767
13,135
18,842
Excess cash
11,717
33,592
45,676
Stockholders' equity
(80,645)
(56,830)
(59,326)
Invested Capital
122,892
121,779
113,108
ROIC
ROCE
EV
Common stock shares outstanding
1,686
1,626
30,714
Price
Market cap
EV
EBITDA
(6,836)
(5,344)
(7,876)
EV/EBITDA
Interest
1,532
4,080
347
Interest/NOPBT